These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17302287)

  • 1. [Use of angiotensin receptor blockers (ARBs) in the metabolic syndrome].
    Sasamura H; Itoh H
    Nihon Rinsho; 2007 Feb; 65(2):381-8. PubMed ID: 17302287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
    Pershadsingh HA
    Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
    Kurtz TW
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].
    Petkow-Dimitrow P
    Pol Arch Med Wewn; 2007 Apr; 117(4):44-50. PubMed ID: 17722475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients.
    Geng DF; Jin DM; Wu W; Xu Y; Wang JF
    Int J Cardiol; 2012 Mar; 155(2):236-42. PubMed ID: 21036409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical utility of angiotensin receptor blockers in out-of-office hypertension (masked hypertension, workplace hypertension, and home hypertension)].
    Yano Y; Kario K
    Nihon Rinsho; 2009 Apr; 67(4):789-98. PubMed ID: 19348244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy].
    Hanefeld M; Metzler W; Köhler C; Schaper F
    Herz; 2006 May; 31(3):246-54; quiz 255. PubMed ID: 16770562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolic syndrome].
    Shimamoto K; Miura T
    Nihon Rinsho; 2009 Apr; 67(4):771-6. PubMed ID: 19348241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
    Yamagishi S; Takenaka K; Inoue H
    Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
    Parhofer KG; Birkeland KI; DeFronzo R; Del Prato S; Bhaumik A; Ptaszynska A
    Int J Clin Pract; 2010 Jan; 64(2):160-8. PubMed ID: 19929980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating the metabolic syndrome.
    Bianchi C; Penno G; Romero F; Del Prato S; Miccoli R
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):491-506. PubMed ID: 17489673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of ARB in metabolic syndrome].
    Kumagai H; Takimoto C; Iigaya K; Kamayachi T; Saruta T; Itoh H
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():599-606. PubMed ID: 17458289
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of angiotensin II receptor blockers on dementia.
    Mogi M; Horiuchi M
    Hypertens Res; 2009 Sep; 32(9):738-40. PubMed ID: 19727113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.